Epidiolex (Cannabidiol) Market Report 2025

This Epidiolex (Cannabidiol) market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The epidiolex (cannabidiol) market size has grown strongly in recent years. It will grow from $3.55 billion in 2024 to $3.89 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. The growth during the historic period can be attributed to an increased focus on patient-centric medical treatments, growing research supporting cannabidiol’s effectiveness in treating epilepsy, rising patient awareness of cannabidiol’s therapeutic potential, a growing demand for alternative treatments to traditional anti-epileptic drugs, and the expanding global demand for medical cannabis products.

The epidiolex (cannabidiol) market size is expected to see strong growth in the next few years. It will grow to $5.55 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The expected growth in the forecast period is driven by factors such as an increase in insurance companies covering Epidiolex, heightened awareness of the side effects of traditional anti-epileptic medications, growing demand for natural, plant-based medicines, a rising number of children and adults diagnosed with epilepsy, and supportive government policies and frameworks for medical cannabis. Key trends in this period include the integration of cannabidiol into established treatment protocols, advancements in manufacturing technologies, partnerships with healthcare organizations, the inclusion of Epidiolex in treatment plans for intractable epilepsy, the use of artificial intelligence in cannabidiol product development, and the development of water-soluble cannabidiol to enhance bioavailability.

The rising prevalence of epilepsy is expected to drive the growth of the Epidiolex (cannabidiol) market. Epilepsy is a neurological disorder characterized by frequent, unprovoked seizures caused by abnormal electrical activity in the brain. The increasing number of epilepsy cases can be attributed to factors such as improved diagnosis, greater awareness, and the growing incidence of conditions such as brain injuries, stroke, and genetic factors. Epidiolex, a prescription medication derived from cannabidiol (CBD), is used to treat certain types of epilepsy by reducing the frequency and severity of seizures through modulation of the brain's signaling pathways. For example, in May 2024, the Centers for Disease Control and Prevention (CDC) reported that approximately 2.9 million U.S. adults aged 18 and older had active epilepsy in 2022, representing about 1% of the adult population. Additionally, around 456,000 children under 18 in the U.S. were estimated to have active epilepsy. As such, the growing prevalence of epilepsy is driving the demand for Epidiolex (cannabidiol).

Companies in the Epidiolex (cannabidiol) market are focusing on developing innovative products, such as synthetic cannabidiol (CBD) formulations, to gain a competitive advantage. A synthetic cannabidiol product is a lab-created version of CBD designed to replicate the therapeutic effects of natural CBD without containing tetrahydrocannabinol (THC). For example, in January 2024, Akumentis Healthcare Ltd., an India-based pharmaceutical company, launched Clasepi, a synthetic cannabidiol (CBD) product approved by the Drug Controller General of India (DCGI). Clasepi is designed to treat seizures associated with conditions such as Lennox-Gastaut Syndrome (LGS), Dravet Syndrome, and Tuberous Sclerosis Complex (TSC) in patients aged 1 year and older. It is the first synthetic CBD product of its kind available in India, containing less than 0.1% THC, making it non-psychotropic. Clinical studies have shown that Clasepi is effective in reducing seizures, particularly in patients who have not responded to traditional antiseizure medications. Proper adherence to healthcare providers' instructions is critical for optimal use and safety.

In January 2022, Dermapharm Holding SE, a Germany-based healthcare company, acquired C³ Cannabinoid Compound Company GmbH for €80 million ($84.08 million). This acquisition helps Dermapharm strengthen its position in the growing cannabis market and expand its distribution channels in Europe, particularly in anticipation of cannabinoid therapy legalization and increasing acceptance. The acquisition also enhances Dermapharm’s ability to develop and market both natural and synthetic cannabinoids, positioning the company for future growth in this expanding sector. C³ Cannabinoid Compound Company GmbH is based in Germany and specializes in the development, production, and marketing of both natural and synthetic cannabinoids.

Major players in the epidiolex (cannabidiol) market are Cannoid LLC, Jazz Pharmaceuticals Plc, Curaleaf Holdings Inc., Trulieve Cannabis Corp., Cresco Labs Inc., Tilray Brands Inc., Columbia Care Inc., Canopy Growth Corporation, Acreage Holdings Inc., Verano Holdings Corp., Aurora Cannabis Inc., Planet 13 Holdings Inc., The Cronos Group Inc., Folium Biosciences LLC, Green Roads of Florida LLC, Medterra CBD LLC, Endoca B.V., CV Sciences Inc., NuLeaf Naturals LLC, Isodiol International Inc., PharmaHemp d.o.o., Koi CBD LLC, Elixinol Global Limited, Vapen CBD LLC, and 180 Life Sciences Corp.

North America was the largest region in the epidiolex (cannabidiol) market in 2024. The regions covered in epidiolex (cannabidiol) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the epidiolex (cannabidiol) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Epidiolex is a prescribed medication containing cannabidiol (CBD), a compound derived from the cannabis plant. It is mainly used to treat two rare and severe forms of epilepsy - Lennox-Gastaut syndrome (LGS) and Dravet syndrome - in patients aged 1 year and older. Epidiolex helps reduce the frequency and severity of seizures by interacting with the endocannabinoid system, although its exact mechanism of action is not completely understood.

The main forms of Epidiolex (cannabidiol) include oral solutions, capsules, and oil solutions. The oral solution is a liquid form of medication taken by mouth, often preferred for pediatric patients or individuals who have difficulty swallowing pills. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and is used for the treatment of epilepsy, Dravet syndrome, Lennox-Gastaut syndrome, and seizure management.

The epidiolex (cannabidiol) market research report is one of a series of new reports that provides epidiolex (cannabidiol) market statistics, including epidiolex (cannabidiol) industry global market size, regional shares, competitors with a epidiolex (cannabidiol) market share, detailed epidiolex (cannabidiol) market segments, market trends and opportunities, and any further data you may need to thrive in the epidiolex (cannabidiol) industry. This epidiolex (cannabidiol) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The epidiolex (cannabidiol) market consists of sales of roasted cannabidiol gummies, vapes, tinctures and sleep aids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.